World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
130
Citations
72096
World Ranking
2470
National Ranking
119

Torsten Haferlach publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Torsten Haferlach sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,512 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Torsten Haferlach D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Torsten Haferlach sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 130 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Torsten Haferlach is affiliated with the MLL Munich Leukemia Laboratory in Germany. Their research primarily focuses on hematology, genetics, and molecular biology, with a significant emphasis on cancer research and immunology. The scientist's work contributes extensively to the understanding and treatment of various blood-related malignancies and disorders.

Haferlach's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Within these areas, they have specialized subfields such as:

  • Hematology
  • Genetics
  • Molecular Biology
  • Cancer Research
  • Immunology

The primary research topics addressed by Haferlach concern:

  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Digital Imaging for Blood Diseases

Their publications have been featured predominantly in the following venues:

  • Blood
  • Leukemia
  • bioRxiv (Cold Spring Harbor Laboratory)
  • HemaSphere
  • Blood Advances

Torsten Haferlach has collaborated frequently with a number of co-authors including:

  • Manja Meggendorfer
  • Claudia Haferlach
  • Wolfgang Kern
  • Wencke Walter
  • Stephan Hütter

Notable recent publications by Haferlach include:

  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms, 2022, Leukemia
  • 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party, 2021, Blood
  • Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN), 2020, Journal of Clinical Oncology
  • SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS, 2020, Blood
  • Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma, 2023, Nature Medicine

Best Publications

  • Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

    T Haferlach;Y Nagata;V Grossmann;Y Okuno

  • Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

    Susanne Schnittger;Claudia Schoch;Martin Dugas;Wolfgang Kern

  • BRAF mutations in hairy-cell leukemia

    Enrico Tiacci;Vladimir Trifonov;Gianluca Schiavoni;Antony Holmes

  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

    Gerrit J. Schuurhuis;Michael Heuser;Sylvie Freeman;Marie Christine Béne

  • Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

    Susanne Schnittger;Claudia Schoch;Wolfgang Kern;Cristina Mecucci

  • Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

    Torsten Haferlach;Alexander Kohlmann;Lothar Wieczorek;Giuseppe Basso

  • Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

    Peter Valent;Amy D. Klion;Hans-Peter Horny;Florence Roufosse

  • Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications.

    Guido Marcucci;Torsten Haferlach;Hartmut Döhner

  • Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

    Peter Valent;Hans-Peter Horny;John M. Bennett;Christa Fonatsch

  • Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia

    Rongqing Pan;Leah J. Hogdal;Juliana M. Benito;Donna Bucci

  • Landscape Of Genetic Lesions In 944 Patients With Myelodysplastic Syndromes

    Yasunobu Nagata;Vera Grossmann;Yusuke Okuno;Ulrike Bacher

  • Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin

    Ramiro Garzon;Michela Garofalo;Maria Paola Martelli;Roger Briesewitz

  • Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)

    Norbert Schmitz;Peter Dreger;Meinolf Suttorp;Ernst B. Rohwedder

  • AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

    Thomas Pabst;Beatrice U. Mueller;Nari Harakawa;Claudia Schoch

  • Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia

    Raphaël Itzykson;Olivier Kosmider;Aline Renneville;Véronique Gelsi-Boyer

  • KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

    Susanne Schnittger;Tobias M. Kohl;Torsten Haferlach;Wolfgang Kern

  • Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients

    Ulrike Bacher;Claudia Haferlach;Wolfgang Kern;Torsten Haferlach

  • Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group.

    Thomas Büchner;Wolfgang Hiddemann;Bernhard Wörmann;Helmut Löffler

  • IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status

    Susanne Schnittger;Claudia Haferlach;Madlen Ulke;Tamara Alpermann

  • Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia

    Kenichi Yoshida;Masashi Sanada;Yuichi Shiraishi;Daniel Nowak

Frequent Co-Authors

Wolfgang Kern
Wolfgang Kern Munich Leukemia Laboratory (Germany)
Claudia Haferlach
Claudia Haferlach Ludwig-Maximilians-Universität München
Susanne Schnittger
Susanne Schnittger Ludwig-Maximilians-Universität München
Claudia Schoch
Claudia Schoch MLL Munich Leukemia Laboratory
Wolfgang Hiddemann
Wolfgang Hiddemann Ludwig-Maximilians-Universität München
Martin Dugas
Martin Dugas Heidelberg University
Seishi Ogawa
Seishi Ogawa Kyoto University
Jaroslaw P. Maciejewski
Jaroslaw P. Maciejewski Cleveland Clinic
Nicholas C.P. Cross
Nicholas C.P. Cross University of Southampton
Mikkael A. Sekeres
Mikkael A. Sekeres Cleveland Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t always mean becoming a doctor. The healthcare field offers a variety of rewarding paths that can be started or advanced through online education. Many students are looking for flexible, affordable ways to grow their careers, making online programs increasingly popular in the U.S.

For those interested in leadership and management roles, an online master of health administration can open doors to jobs across hospitals, clinics, and health organizations. To keep tuition costs down, students often search for the cheapest mha online programs that don’t compromise on quality or accreditation.

Nursing professionals can advance further by choosing one of the cheapest online bsn to dnp programs, earning the highest clinical nursing degree online. Additionally, those fascinated by pharmaceuticals may pursue online pharmacy programs for advanced pharmacy practice and leadership.

Exploring these online options provides flexibility, financial savings, and a valuable way to start or advance a healthcare career—no matter where you live.

Best Scientists Citing Torsten Haferlach

Trending Scientists

Recently Published Articles